Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
To develop a method for predicting outcomes in acute myelogenous leukemia (AML) , we analyzed a number of leukemia bone marrow samples by DNA microarray and identified 68 genes that may be related to patient outcomes. Cluster analysis by comparison with a previously reported scoring system to predict outcomes showed that outcomes in AML could be classified as good or poor on the basis of 20 genes. To examine the usefulness of this 20-gene set, the expression of the genes was examined in bone marrow samples from patients for whom outcomes were already known as a validation cohort. We also used DNA microarray to identify genes involved in the transformation from myelodysplastic syndrome to AML and examined them further in detail.
|